THOUSAND OAKS, Calif. (April 16, 2013) – Amgen today announced that it has executed a civil settlement agreement to settle the fourth of five previously disclosed qui tam actions filed against Amgen that were made known to the company in connection with discussions that resulted in an October 2011 agreement in principle to settle different allegations related to Amgen’s sales and marketing practices. The first of these five other qui tams was settled in December 2012 along with the matters covered by the October 2011 agreement in principle. Amgen has been dismissed from two of the other qui tams. In late 2012, Amgen announced an agreement in principle to resolve the fourth other qui tam and today announced the execution of a civil settlement agreement for this matter currently pending in U.S. federal court in South Carolina. The South Carolina settlement agreement related primarily to allegations that Amgen’s market share rebate agreements with various long-term care pharmacy providers and the therapeutic interchange programs allegedly instituted by the long-term care pharmacy providers over the early- to mid-2000s did not comply with the safe harbor requirements of the Anti-Kickback statute. Amgen denied all of these allegations that were resolved by the settlement.